After $1 Million Drug Flop, UniQure Seeks Gene-Therapy Revival – Bloomberg
|
After $1 Million Drug Flop, UniQure Seeks Gene–Therapy Revival
Bloomberg UniQure is also developing experimental gene therapies for Huntington’s disease and collaborating with Bristol-Myers Squibb Co., which owns about 7.5 percent of the shares, on treatments for cardiovascular illnesses. The company would consider new … |
|
Crispr: vragen rond het wondermiddel voor de ‘betere mens’
Het Financieele Dagblad Dat patent heeft bovendien slechts betrekking op andere systemen (Cascade en Cpf1) dan het nu veel gebruikte Cas9. Van der Oost maakt zich nog het meeste zorgen om wat er straks met het intellectuele eigendom van Crispr gebeurt. Veel patenten zijn … |
|
An index measures similarity between cancer cells and pluripotent stem cells
Science Daily In a study whose findings were published in the journal Cell on Thursday, May 5, researchers at the University of São Paulo’s Ribeirão Preto Medical School (FMRP-USP) in Brazil and collaborators in several other countries describe a method that … |
EurekAlert (press release) |
New immunotherapy for lung cancer shows promise of success …
EurekAlert (press release) In a groundbreaking development at the MUSC Hollings Cancer Center, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease’s progression. The study … |